Beginning in 2013 as Qualcomm Wireless Scholar, as PI led the design of next generation digital medicine clinical trials that includes SaMD, DHTs, RPM, and machine learning studies for product development, regulatory approval, and clinical use. - Designed small to late stage DHT/ML clinical trials including N-of-1, community-based participatory, global health, cluster randomized, and new embedded EMR trial designs. - Granted 510K, Breakthrough designation, and Pre-Market Approval for various devices. - Raised 600M in extramural and venture funding across DHT and AI developers. I practice clinical cardiology in multipractice facility in East County of San Diego that extends to border communities and in rural and dessert communities across Southeastern California. - Collectively executed technology-based patient care programs across the United States, Canada, and in resource limited areas - Uganda, India, Kenya, and Mexico- creating the first smartphone-connected digital health clinics. - Telehealth services in COVID­‐19 and the development of patient-generated data for remote monitoring in patients with heart failure, hypertension, and arrhythmias.- Implemented machine learning algorithms for in-patient and outpatient settings.

Principal Investigator of product development and the design and validation of a new earbud form factor for cardiovascular applications and continuous hemodynamic measurements included ECG, central blood pressure, and cardiovascular time intervals.

Principal investigator of a multi-center, umbrella clinical trial to develop and validate new digital health and machine learning products for cardiopulmonary diseases.

Senior principal investigator responsible for design, oversight, and execution of AED product development and CNN ML algorithm validation towards successful FDA class III approval

Led a portfolio of product designs and clinical programs including: form factor studies (single lead and 6-lead devices), patient preference pricing model, custer randomized trials, EMR integration (EPIC, GE Muse) methods, developed the independent diagnostic testing facility, and created the first Smartphone ECG remote monitoring RPM CPT programs. Advised on series E.

Led the research and clinical strategies for BIOCOM life science members across industry, academia, and healthcare institutions (>1000 members). Provided review and responses to the 21st Century Cures Act and CONNECT legislations.

Chair of the Data Safety Monitoring Board responsible for overseeing a portfolio of clinical trials investigating the ingestible sensor in Hepatitis C, Tuberculosis, Heart Failure, and in Hypertension. Provided planning and oversight for pharmaceutical compounding in heart failure and hypertension medications, and developed real world models for ingestible sensor chronic care management.

Responsible for developing and executing go to market clinical strategies for the suite of Cardiex digital health technologies within new consumer, clinic, and hospital based models of care.

Nominated by the American College of Cardiology to join the FDA’s Digital Health Center of Excellence to spearhead clinical strategies within cross center policy, device development clinical trials, post-market evidentiary approaches, and to advance equity strategic priorities. - Co-authored the DHT in Clinical Trials, DHT device data standards, AI/ML in Drug Discovery, and Real-World Evidence discussion papers and guidance documents. - Clinical representative on the International Medical Device Regulators Forum for Software as a Medical Device global workgroup. - Clinical advisor to the Total Product Life Cycle (TPLC) breakthrough device sponsors for post-market trials and clinical use considerations. - Provide medical and scientific expertise to opioid use disorder, ALS, COVID, MPOX, bias in ML, RPM, PGHD, and synthetic data priorities.- Lead program officer for FDA-Stanford CERSI partnership.- Support the Office of Strategic Partnerships & Technology Innovation, CDRH, CDER, and the Office of the Commissioner as needed.

Innovation advisor to the office of the CIO, CSO, and CEO of the American College of Cardiology. Responsible for developing the ACC's Roadmap for Innovation and Health Policy Statement that led the curation and expansion of multiple digital health and artificial intelligence activities: - Chair of the ACCs Innovation Advisory Group- Appointed to the Digital Transformation Task Force on behalf of the Board of Trustees - Informed the ACC's acquisition of MediAxiom (a practice management company)- Organized 'FutureHub' at the Scientific Sessions that brought together the clinical, industry, and academic sectors. - Led the expansion of ACC's Innovation Member Section to 3,000+ members

Steering committee member on the PACES (Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG) international, multi-center, randomized outcome trial. - Responsible for designing a nested digital health study to prospectively detect and quantify the burden of atrial fibrillation with a wearable continuously monitoring telemetry device.-The digital health study is the first nested design within an NHLBI/NIH multicenter, randomized trial, and coordination between 25 large academic healthcare institutions.

(2018-2021) Pfizer-Bristol Meyers Squibb - Digital Health Board of Advisors - Advisory roles to inform the expansion of the ARISTA funding program to DHT/AI. - Provided strategic priorities and curation and selection of DHT and AI/ML products within the CV and metabolic product portfolio. - Developed new digital patient engagement programs (atrial fibrillation and heart failure) for commercialization.(2018-2022) Corvista - Medical Advisory Board - Responsible for scientific development within the heart failure and coronary artery disease DHT/ML product development clinical trials.(2015-2019) Proteus Digital - Chair Data Safety Monitoring Board- Responsible for overseeing a portfolio of clinical trials investigating the ingestible sensor in Hepatitis C, Tuberculosis, Heart Failure, and in Hypertension.- Provided strategic planning and operational oversight for pharmaceutical compounding in heart failure and hypertension medications, and developed real world models for ingestible sensor chronic care management. - Advised on the completion and termination of these trials and programs during chapter 11(2019-2022) - Infinion Semiconductor - Board of Advisors - Responsible for strategic planning for radar technology development and applications in healthcare(2018-2020) Anthem AI - Board of Advisors(2017-2021) Kardiogenics - Board of Advisors